Fifteen-year follow-up from the S0016 trial suggests that some patients with advanced-stage follicular lymphoma may be cured with standard chemoimmunotherapy, according to Dr. Jonathan W. Friedberg, ...

Dr Alison Oliver has spoken out after a lifeline drug has been blocked by health bosses.

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

NEW ORLEANS - Ochsner MD Anderson Cancer Center will be the first in the South to offer Biology-Guided Radiotherapy, joining ...

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

The foundation helps fund youth sports programs, cancer organizations and mental health nonprofits, delivering the message ...

A charity which started around a kitchen table is making a difference to people being treated for cancer. Chemotivation, founded in Hatherleigh, Devon, has handed out 150 of what volunteers call Hope ...

Hutchmed announces update on licensed oncology product Tazverik in China: Hong Kong, Shanghai Wednesday, March 11, 2026, 15:00 Hrs [IST] Hutchmed (China) Limited, an innovative, c ...

Concerns about mold allegedly linked to multiple patient deaths has emerged at Queen Elizabeth University Hospital, one of ...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has launched a capital raising of up to $20 million through a combination of an institutional placement and a share purchase plan (SPP), with funds earmarked ...